Compare Fresenius Medical Care AG & Co. KGaA (FMS) vs Solventum Corporation (SOLV) Stock

Solventum Corporation (SOLV) offers the better valuation at 8.4x trailing P/E (11.5x forward), making it the more compelling value choice. Analysts rate Solventum Corporation (SOLV) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Solventum Corporation (SOLV) is the cheapest at 8.4x versus Fresenius Medical Care AG & Co. KGaA at 11.8x. On forward P/E, Fresenius Medical Care AG & Co. KGaA is actually cheaper at 9.9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Solventum Corporation (SOLV) delivered a total return of -7.3%, compared to -22.8% for Fresenius Medical Care AG & Co. KGaA (FMS). A $10,000 investment in SOLV five years ago would be worth approximately $9K today (assuming dividends reinvested). Over 10 years, the gap is even starker: SOLV returned -7.2% versus FMS's -28.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Fresenius Medical Care AG & Co. KGaA (FMS) is the lower-risk stock at 0.40β versus Solventum Corporation's 0.97β — meaning SOLV is approximately 141% more volatile than FMS relative to the S&P 500. On balance sheet safety, Fresenius Medical Care AG & Co. KGaA (FMS) carries a lower debt/equity ratio of 76% versus 100% for Solventum Corporation — giving it more financial flexibility in a downturn.

Solventum Corporation (SOLV) is the more profitable company, earning 18.7% net margin versus 5.0% for Fresenius Medical Care AG & Co. KGaA — meaning it keeps 18.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SOLV leads at 26.2% versus 9.3% for FMS. At the gross margin level — before operating expenses — SOLV leads at 53.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Fresenius Medical Care AG & Co. KGaA (FMS) trades at 9.9x forward P/E versus 11.5x for Solventum Corporation — 1.6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SOLV: 29.1% to $95.80.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Fresenius Medical Care AG & Co. KGaA (FMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.40)). Both have compounded well over 10 years (FMS: -28.5%, SOLV: -7.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.